Introduction {#s1}
============

The lateral hypothalamus (LH) has long been known to be involved in the regulation of sleep/wakefulness, feeding behavior and metabolism ([@bib56]). Orexin/hypocretin-(encoded by the *Hcrt* gene) and melanin-concentrating hormone (MCH, encoded by the *Pmch* gene)-producing neurons are distributed within the LH; MCH neurons also extend caudally into the zona incerta. Orexin and MCH neurons project throughout the brain ([@bib6]; [@bib43]; [@bib41]) and are implicated in feeding and sleep/wakefulness ([@bib47]; [@bib53]; [@bib12]; [@bib62]).

*Hcrt* ([@bib12]) or *Hcrtr2* ([@bib65]) gene knockout mice and orexin neuron-ablated mice ([@bib19]; [@bib55]) display a narcolepsy-like phenotype. Narcolepsy is a chronic sleep disorder ([@bib34]) caused by the specific degeneration of orexin neurons by the immune system ([@bib44]; [@bib31]). Narcolepsy patients have characteristic symptoms including excessive daytime sleepiness, hallucinations and cataplexy, a sudden loss of muscle tone triggered by positive emotions such as laughter ([@bib2]; [@bib11]). Optogenetic activation of orexin neurons induces wakefulness from sleep while optogenetic inhibition induces sleep from wakefulness ([@bib1]; [@bib59]; [@bib52]; [@bib64]). Together, these studies indicate that orexin neurons play an important role in the maintenance of wakefulness and prevent cataplexy induced by positive emotions.

The neuropeptide MCH was originally isolated from fish pituitary as a substance that controls skin pigmentation ([@bib27]). In mammals, MCH neurons are mainly distributed in the tuberal hypothalamus within which the orexin neurons are also located. Optogenetic activation of MCH neurons increases the total time in rapid eye movement (REM) sleep and reduces non-REM (NREM) sleep in mice ([@bib26]; [@bib29]; [@bib60]). Ablation of MCH neurons promotes wakefulness and decreases time in NREM sleep but has no effect on REM sleep ([@bib60]). These observations suggest that MCH neurons are likely involved in the regulation of both NREM and REM sleep. We recently reported that REM sleep-active MCH neurons are involved in memory erasure during REM sleep ([@bib24]), further supporting the concept that MCH neurons are involved in multiple physiological functions ([@bib17]; [@bib4]).

While the orexin and MCH neurons have different roles in the regulation of sleep/wakefulness ([@bib30]), they have similar projection areas and receptor distributions ([@bib58]; [@bib23]; [@bib28]; [@bib35]; [@bib46]). Orexin and MCH neurons have also been reported to interact with each other. For example, application of orexin peptide increases spike frequency in MCH neurons in vitro ([@bib61]) and optogenetic activation of orexin neurons inhibits MCH firing through GABA~A~ receptors ([@bib3]), while MCH reverses hypocretin-1-induced enhancement of action potentials in orexin neurons ([@bib45]). Nevertheless, it is still unclear how interactions between orexin and MCH neurons contribute to sleep/wake regulation.

To understand the functional communication between orexin and MCH neurons and sleep/wakefulness regulation, we generated transgenic mice in which both orexin and MCH neurons were simultaneously ablated by tetracycline trans-activator (tTA)-induced expression of the diphtheria toxin A fragment (DTA). Analysis of the sleep patterns of orexin and MCH neuron double-ablated mice (OXMC mice) revealed that these mice exhibited very high levels of cataplexy and sleep/wake abnormalities. OXMC mice had increased wakefulness and profound reductions in REM sleep (particularly during the dark phase) and a corresponding increase in cataplexy, suggesting that MCH neurons have a suppressive role on cataplexy. OXMC mice also frequently showed short episodes of behavioral arrest with high δ and θ power. We defined this unique state as 'delta-theta sleep' (DT sleep) since this state was distinct from other states of sleep/wakefulness or cataplexy. Behavioral and pharmacological assessments showed some similarities as well as characteristic differences between DT sleep and cataplexy.

Results {#s2}
=======

Dual ablation of orexin and MCH neurons using the tetracycline transactivator (tTA)/TetO system {#s2-1}
-----------------------------------------------------------------------------------------------

We previously reported that *Hcrt-tTA; TetO DTA* (OX) mice ([@bib55]) or *Pmch-tTA; TetO DTA* mice ([@bib60]) enabled us to induce specific ablation of orexin neurons or MCH neurons in a timed-controlled manner, respectively. Here, we generated triple transgenic *Hcrt-tTA* (Tg/-)*; Pmch-tTA* (Tg/-); *TetO DTA* (Tg/-) (OXMC) mice to enable simultaneous ablation of both orexin and MCH neurons ([Figure 1A](#fig1){ref-type="fig"}). DTA induces cell death by inactivating eukaryotic elongation factor 2 through ADP ribosylation, thereby blocking protein synthesis. DTA expression can be controlled by the presence or absence of doxycycline (DOX)-containing chow since the Tet-off system is used to control the timing of DTA expression ([Figure 1B](#fig1){ref-type="fig"}). In situ hybridization confirmed that MCH neurons and orexin neurons co-expressed *Slc17a6* (encoding vesicular glutamate transporter: vGlut2) mRNA but not *Slc32a1* (encoding vesicular inhibitory amino acid transporter: vGAT) mRNA. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} indicates that most MCH and orexin neurons are co-localized with vGlut2 (MCH neurons: 96.3 ± 3.1%, n = 4; orexin neurons: 99.6 ± 0.2%, n = 5) but not with vGAT (MCH neurons: 5.1 ± 0.9%, n = 4; orexin neurons: 1.7 ± 0.9%, n = 3), suggesting that most MCH and orexin neurons are glutamatergic rather than GABAergic neurons as also suggested by others ([@bib36]; [@bib37]). Although MCH neurons and orexin neurons were a relatively minor subset of the LH glutamatergic neuron population (MCH neurons: 14.6 ± 2.4% (n = 4); orexin neurons: 23.6 ± 3.2% (n = 5)).

![Dual ablation of orexin and MCH neurons using the tetracycline tTA/TetO system.\
(**A**) Schematic illustrating generation of *Hcrt-tTA* (Tg/-); *Pmch-tTA* (Tg/-); *TetO DTA* (Tg/-) mice. (**B**) Schematic showing use of the tetracycline-controlled Tet-off gene expression system. In the presence of DOX (light blue circle), DOX binds to tTA (purple oval) and DTA expression is blocked. The absence of DOX allows tTA to bind TetO, allowing transcription of the diphtheria toxin A (DTA) subunit which results in cell death. (**C**) Experimental protocols for sleep recording and immunostaining. Protocol I is the control (DOX(+)) condition; Protocol II is the experimental (DOX(-) for 4 weeks) condition. EEG and EMG surgeries were performed at age 10 weeks in the sleep-recording group; the mice used for immunostaining did not undergo surgery. Light blue and white bars represent the periods of DOX chow (DOX(+)) and normal chow (DOX(-)) availability, respectively. Gray bars indicate sleep recordings; red arrows indicate when mice were sacrificed for immunostaining. (**D**) Immunostaining of orexin (brown) and MCH (black) neurons in the LH at DOX(-) 0 week (i and v), 2 weeks (ii and vi), 4 weeks (iii and vii), and DOX(+) 4 weeks (iv and viii). Black and brown arrowheads indicate typical examples of orexin and MCH neurons, respectively. Panels v-viii are magnifications of the areas delineated by the squares in Panels i-iv. Scale bars: i-iv, 500 µm; v-viii, 100 µm. (**E**) The number of orexin and MCH neurons in OXMC mice from the DOX(+) and (-) conditions (n = 3--6). Values are mean ± SEM. \*p\<0.05 vs. DOX(+). Data were analyzed by unpaired *t* test.\
Figure 1---source data 1.Source data for [Figure 1E](#fig1){ref-type="fig"}.](elife-54275-fig1){#fig1}

[Figure 1C](#fig1){ref-type="fig"} illustrates the timing of DOX on (+), DOX off (-), sleep recording and immunostaining. In OXMC mice, both orexin and MCH neurons were simultaneously ablated by expressing DTA in the absence of DOX ([Figure 1B](#fig1){ref-type="fig"}). [Figure 1D](#fig1){ref-type="fig"} shows representative immunostaining of orexin and MCH neurons. The number of orexin neurons in OXMC mice in the DOX(+) condition at 0, 2 and 4 weeks was 810 ± 86 (100%, n = 3), 849 ± 20 (104.9%, n = 3) and 841 ± 47 (103.8%, n = 4), respectively. The number of MCH neurons at 0, 2 and 4 weeks was 1031 ± 54 (100%, n = 3), 958 ± 12 (92.9%, n = 3) and 1185 ± 118 (114.9%, n = 4), respectively. Conversely, the number of orexin neurons in OXMC mice in the DOX(-) condition at 2 and 4 weeks was 226 ± 34 (26.6%, n = 3, p\<0.05 vs. DOX(+) 2 w) and 16 ± 3 cells (1.8%, n = 6, p\<0.05 vs. DOX(+) 4 w), respectively. The number of MCH neurons at 2 and 4 weeks was 527 ± 1 (55.0%, n = 3, p\<0.05 vs. DOX(+) 2 w) and 38 ± 10 cells (3.2%, n = 6, p\<0.05 vs. DOX(+) 4 w), respectively ([Figure 1E](#fig1){ref-type="fig"}). These results confirmed that orexin and MCH cell bodies were ablated by removal of DOX from chow.

Orexin neurons and MCH neurons project widely throughout the brain. Dense projections of orexin neurons have been described in the locus coeruleus (LC) and raphe nucleus ([@bib43]; [@bib15]). MCH neurons densely innervate the medial septum (MS) and hippocampus ([@bib26]; [@bib24]). In OXMC mice maintained for 4 weeks in the DOX(-) condition, orexin and MCH nerve terminals in these projection sites were completely eliminated ([Figure 2](#fig2){ref-type="fig"}). These results confirmed that, not only the cell bodies, but also the projections of orexin and MCH neurons were eliminated in OXMC mice after DOX(-) for 4 weeks.

![Time course of orexin and MCH nerve terminal ablation in projection areas.\
(**A**) Immunostaining of MCH nerve terminals (black) in the medium septum (MS). (**B**) Immunostaining of orexin nerve terminals (black) and tryptophan hydroxylase (Tph; brown) in the raphe nucleus. (**C**) Immunostaining of orexin nerve terminals (black) and tyrosine hydroxylase (TH; brown) in the locus coeruleus (LC). Photos indicate DOX(-) condition at week 0 (i and v), 2 weeks (ii and vi), 4 weeks (iii and vii) and the DOX(+) condition at 4 weeks (iv and viii). Panels v-viii are magnifications of the areas delineated by the squares in Panels **i-iv**. Scale bars: i-iv, 500 µm; v-viii, 100 µm.](elife-54275-fig2){#fig2}

Dual-ablated mice frequently displayed short behavioral arrests with high spectral power in the δ and θ bands of the EEG during wakefulness {#s2-2}
-------------------------------------------------------------------------------------------------------------------------------------------

Sleep and wakefulness was assessed in three groups of mice, OXMC DOX(-), OXMC DOX(+) and OX DOX(-) mice by EEG and EMG recording ([Figure 3A](#fig3){ref-type="fig"}). Spectral analyses of the EEG and EMG during wakefulness, NREM and REM sleep were indistinguishable across the three groups in the DOX(+) condition (before DOX removal, [Figure 4A and B](#fig4){ref-type="fig"}). After DOX removal, there was no difference in EEG spectrum and EMG integral of OXMC DOX(-) mice during any vigilance state as neuronal ablation proceeded ([Figure 4C, D and E](#fig4){ref-type="fig"}). These results indicate that neither orexin nor MCH neuron ablation affected the EEG power spectrum in any vigilance state.

![Criteria used to classify DT sleep.\
(**A**) Representative EEG and EMG traces and EEG power spectral density during NREM and REM sleep for OXMC mice after 4 weeks in the DOX(+) and DOX(-) conditions and for OX mice after 4 weeks in the DOX(-) condition. (**B**) Representative EEG and EMG traces and EEG power spectral density during cataplexy in OXMC DOX(-) and OX DOX(-) mice. (**C**) Representative EEG and EMG traces and EEG power spectral density during DT sleep in OXMC DOX(-) mice. DT sleep was characterized by low EMG amplitude with high EEG spectral power in the δ (1--5 Hz) and θ (6--10 Hz) bandwidths. (**D**) Relative EEG power during NREM, REM, cataplexy and DT sleep in OXMC DOX(-) mice (n = 6--8) from 0 to 4 weeks DOX(-). The greatest EEG power across all stages was set at 100% for each mouse. Values are presented as mean ± SEM. (**E**) Relative EEG power in the standard frequency bands (δ, θ, α and β) for each state. The sum of each band is 100%. Values are presented as mean ± SEM. \*p\<0.05. Data were analyzed by one-way ANOVA followed by the Bonferroni *post hoc* test. Despite comparable EMG levels, DT sleep has significantly greater spectral power in the δ range and less power in the θ range than either REM sleep or cataplexy.\
Figure 3---source data 1.Source data for [Figure 3D and E](#fig3){ref-type="fig"}.](elife-54275-fig3){#fig3}

![DOX removal from the diet in OXMC mice does not affect relative EEG power distribution or the EMG integral.\
(**A**) Relative EEG power in three strains of mice in the DOX(+) condition (before DOX removal) during the dark phase. Upper graphs show relative EEG power at 1 Hz resolution; lower graphs present the standard EEG frequency bands. (**B**) As in (**A**) but for the light phase. (**C**) Relative EEG power of OXMC mice measured during the dark phase from 0 to 4 weeks in the DOX(-) condition. Upper graphs show relative EEG power at 1 Hz resolution; lower graphs present the standard EEG frequency bands. (**D**) As in (**C**) but for the light phase. (**E**) EMG integral of OXMC mice in the DOX (-) condition. n = 6--8, Values are mean ± SEM.\
Figure 4---source data 1.Source data for [Figure 4A-E](#fig4){ref-type="fig"}.](elife-54275-fig4){#fig4}

Ablation of orexin neurons is known to induce narcolepsy-like symptoms, such as fragmentation of sleep and wakefulness, sleep onset REM sleep, and cataplexy-like behavioral arrests ([@bib19]; [@bib55]). Since orexin neurons were ablated in both OX DOX(-) and OXMC DOX(-) mice, these mice showed cataplexy-like behavioral arrests but OXMC DOX(+) mice did not ([Figure 3B](#fig3){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). In addition, OXMC DOX(-) mice frequently showed behavioral arrest episodes that were similar to cataplexy ([Video 1](#video1){ref-type="video"}) but which occurred after a sustained period of wakefulness. However, these behavioral arrest episodes were different from cataplexy based on a number of criteria ([Table 2](#table2){ref-type="table"}), particularly the EEG, which showed high amplitude spectral power in the δ and θ bandwidths during the behavioral arrests ([Figure 3C](#fig3){ref-type="fig"}). These episodes were defined as a sudden cessation of motor activity characterized by decreased EMG and relatively high-power ratios of δ and θ in the EEG, preceded by at least 40 s of wakefulness (10 epochs) and followed by a return to wakefulness. The relative power ratio of δ and θ bands during these arrests was significantly different from NREM sleep, REM sleep or cataplexy ([Figure 3D and E](#fig3){ref-type="fig"}). Consequently, we called the state during these arrests 'delta/theta sleep' (DT sleep). These results suggest that DT sleep is a novel brain state different from other states, as defined by EEG spectral characteristics.

###### Comparison of parameters between orexin neuron-ablated mice and orexin MCH-blated mice.

Table 1---source data 1.Source data for [Table 1](#table1){ref-type="table"}.

  Parameter                                                 Orexin neuron-ablated mice   Orexin and MCH-ablated mice   \- fold Difference (OXMC/OX)   *P* value
  --------------------------------------------------------- ---------------------------- ----------------------------- ------------------------------ -----------
  Earliest detection timing of cataplexy                    2 weeks post-ablation        2 weeks post-ablation         N/A                            N/A
  Time-of-day occurrence at 4 weeks                         Both light and dark phases   Both light and dark phases    N/A                            N/A
  Total time in wakefulness during dark phase at 4 weeks    418.9 ± 20.2 min             571.0 ± 22.2 min              1.36                           1.4E-03
  Total time in NREM sleep during dark phase at 4 weeks     258.3 ± 16.2 min             90.5 ± 19.8 min               0.35                           2.8E-04
  Total time in REM sleep during dark phase at 4 weeks      25.6 ± 0.9 min               2.7 ± 1.7 min                 0.10                           4.3E-06
  Total time in wakefulness during light phase at 4 weeks   278.1 ± 19.7 min             322.6 ± 7.3 min               1.16                           3.1E-02
  Total time in NREM sleep during light phase at 4 weeks    389.8 ± 17.4 min             340.1 ± 8.1 min               0.87                           1.6E-02
  Total time in REM sleep during light phase at 4 weeks     46.3 ± 3.4 min               20.8 ± 4.2 min                0.45                           2.7E-03
  Total time in cataplexy in dark phase at 4 weeks          11.0 ± 0.6 min               31.2 ± 3.6 min                2.83                           2.6E-03
  Number of cataplexy bouts in dark phase at 4 weeks        14.8 ± 2.0                   16.9 ± 2.1                    1.14                           0.53
  Mean bout duration in dark phase at 4 weeks               53.3 ± 7.6 sec               113.0 ± 9.6 sec               2.12                           2.2E-03
  Total time in cataplexy in light phase at 4 weeks         5.4 ± 0.9 min                24.2 ± 4.5 min                4.45                           1.4E-02
  Number of cataplexy bouts in light phase at 4 weeks       8.3 ± 1.4                    15.4 ± 3.1                    1.87                           0.13
  Mean bout duration in light phase at 4 weeks              50.0 ± 11.4 sec              96.3 ± 4.8 sec                1.93                           1.7E-03

###### Comparison of parameters between DT sleep and cataplexy.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                             DT sleep                                           Cataplexy
  ----------------------------------------------------- -------------------------------------------------- -----------------------------------------------------------------------
  Neuron dependence                                     Loss of both MCH and orexin neurons necessary      Only loss of orexin neurons required; loss of MCH neurons exacerbates

  EMG amplitude                                         Low                                                Low

  Delta EEG spectral power                              High                                               Low

  Theta EEG spectral power                              High                                               High

  Earliest detection                                    1 week post-ablation                               2 weeks post-ablation

  Progressive increase as neurodegeneration proceeds?   No                                                 Yes

  Time-of-day occurrence                                Both light and dark phases                         Primarily in dark phase in OX mice; both phases in OXMC mice

  Occurrence                                            Spontaneous                                        Spontaneous

  Mean bout duration                                    Similar during both light and dark phases:\~15 s   Similar during both light and\
                                                                                                           dark phases:\~50 s in OX mice but \~ 100 s in OXMC mice

  Response to tactile stimulation                       High; immediate arousal                            Low

  Position in home cage during occurrence               Random                                             Random

  Grooming more likely to precede occurrence            Yes                                                No

  Running more likely to precede occurrence             No                                                 Yes

  Response to chocolate                                 No effect                                          Increased

  Response to clomipramine                              No effect                                          Decreased

  Response to modafinil                                 Decreased                                          No effect
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Typical behavior for DT sleep in orexin- and MCH neuron-ablated mice.

Effect of dual ablation of orexin and MCH neurons on sleep and wakefulness {#s2-3}
--------------------------------------------------------------------------

The sleep/wakefulness patterns of OXMC mice were analyzed during the simultaneous ablation of both the orexin and MCH neurons. [Figure 5A](#fig5){ref-type="fig"} presents typical 24 hr hypnograms observed during the first 4 weeks of orexin and MCH neuron ablation. Sleep/wakefulness fragmentation was observed in both OXMC DOX(-) and OX DOX(-) mice by 1 week in the DOX(-) condition, particularly at the beginning of the dark phase ([Figure 5A](#fig5){ref-type="fig"}). Cataplexy was detected from 2 weeks DOX(-) onwards in both OXMC DOX(-) and OX DOX(-) mice ([Figure 5A, C and D](#fig5){ref-type="fig"}). DT sleep was only observed in OXMC mice; the first episode was detected at 1 week DOX(-), a week earlier than the initial observation of cataplexy at 2 weeks DOX(-). Since DT sleep often occurred during the early dark phase, [Figure 5B](#fig5){ref-type="fig"} presents an expanded hypnogram for 1 hr in the early dark phase at 4 weeks DOX(-) (the period enclosed by the magenta rectangle in [Figure 5A](#fig5){ref-type="fig"}). The mean DT sleep duration and number of DT bouts during the dark phase after 4 weeks of DOX(-) were 14.4 ± 0.7 s and 98.3 ± 6.2, respectively ([Figure 5C](#fig5){ref-type="fig"}). Although the total time and the number of DT sleep bouts observed during the light phase progressively increased by 4 weeks after DOX removal, neither the total time, mean bout duration nor the number of DT sleep bouts progressively increased during the dark phase as ablation proceeded ([Figure 5C and D](#fig5){ref-type="fig"}). Interestingly, the mean DT sleep bout duration appeared to plateau at \~15 s in both the light and dark phases by 2 weeks post-ablation ([Figure 5C and D](#fig5){ref-type="fig"}).

![Effects of dual orexin- and MCH-neuron ablation on sleep/wake architecture in OXMC mice.\
(**A**) Hypnograms from OXMC DOX(+), OXMC DOX(-) and OX DOX(-) mice before (0 week) and during dual orexin and MCH neuron ablation (1--4 weeks). Clock time and light-dark phase are shown below the hypnograms. D, DT sleep; C, cataplexy; W, wake; NR, NREM sleep; R, REM sleep. (**B**) Hypnograms for the 1 hr period after dark onset indicated by magenta rectangles in the 4 weeks hypnogram in A. (**C**) Total duration (upper panels), number of bouts (middle) and mean bout duration (lower panels) for wake, NREM, REM, cataplexy and DT sleep during the dark phase. (**D**) As in C but for the light phase. Values are means ± SEM. (OXMC DOX(+): (n = 7), OXMC DOX(-): (n = 8), OX DOX(-): (n = 4)). \*p\<0.05 vs OXMC DOX(+). ^\#^p\<0.05 vs OX DOX(-). Data were analyzed by one-way ANOVA followed by the Bonferroni *post hoc* test.\
Figure 5---source data 1.Source data for [Figure 5A-D](#fig5){ref-type="fig"}.](elife-54275-fig5){#fig5}

To clarify the functional role of MCH neurons, the total time, mean bout duration and the number of bouts of each vigilance state were compared at each stage of ablation. The total wakefulness time significantly increased in OXMC DOX(-) mice at 4 weeks after DOX removal in the both light and dark phases as compared with OX DOX(-) mice ([Figure 5C and D](#fig5){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). Conversely, except for NREM sleep during the light period, OXMC DOX(-) mice exhibited a significant reduction in total REM and NREM sleep and the number of bouts in both light and dark phases at 4 weeks DOX(-) when compared with OX DOX(-) ([Figure 5C and D](#fig5){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). The total time in cataplexy and mean cataplexy bout duration was greater in OXMC DOX(-) mice as compared with OX DOX(-) mice ([Figure 5C and D](#fig5){ref-type="fig"} and [Table 1](#table1){ref-type="table"}), indicating that the loss of MCH neurons exacerbated cataplexy symptomatology. [Table 1](#table1){ref-type="table"} summarizes the vigilance state and cataplexy characteristics in OXMC DOX(-) mice compared to OX DOX(-) mice. The differences in sleep/wakefulness phenotype between these two strains suggest that MCH neurons are part of a circuit that normally suppresses cataplexy.

Behavioral assessment of DT sleep {#s2-4}
---------------------------------

To determine whether DT sleep is different from cataplexy or sleep, we performed tactile stimulation on OXMC DOX(-) mice during cataplexy, NREM or DT sleep. Although mice rarely responded to tactile stimulation during cataplexy ([Video 2](#video2){ref-type="video"}), they always responded to tactile stimulation during NREM or DT sleep by escaping the source of stimulation. [Figure 6A](#fig6){ref-type="fig"} illustrates that the probability of wakefulness was 33% after tactile stimulation during cataplexy compared to 100% in NREM and DT sleep. Mice could sense the touch of the brush and escaped during DT sleep and NREM sleep ([Video 3](#video3){ref-type="video"}). These results suggest that DT sleep differs from cataplexy and may be more similar to NREM sleep.

![DT sleep is distinct from cataplexy.\
(**A**) Upper panels show representative traces of EEG and EMG when tactile stimulation (arrowheads) was performed during cataplexy, DT sleep and NREM sleep in OXMC DOX(-) mice after 4 weeks in the DOX(-) condition. Lower panels show the percentage of each state 1 min before and 1 min after tactile stimulation. Vigilance states were determined in 4 s epochs. Bar graphs shows the percentage of wakefulness during the first 3 epochs (12 s) after tactile stimulation during cataplexy, DT sleep (DT) and NREM sleep (NR). \*p\<0.05, one-way ANOVA followed by the Bonferroni *post hoc* test (OXMC DOX(-) (n = 6)). (**B**) Schematic drawing of home cage (upper left) showing location of nest and water bottle and corresponding picture (lower left). Bar graphs show the percentage of DT sleep (DT), cataplexy (C), NREM (NR), and REM sleep (R) occurring in the nest area in OXMC (-) mice. Dashed line in the bar graph indicates chance level (25%). \*p\<0.05, one-way ANOVA followed by the Bonferroni *post hoc* test (OXMC DOX(-) (n = 7)). (**C**) Bar graphs indicate the behaviors observed before cataplexy and DT sleep. Values are mean ± SEM. \*p\<0.05, paired t-test (OXMC DOX(-) (n = 7)). (**D**) Total time, number of bouts and mean bout duration of cataplexy and DT sleep during the dark and light phases in OX DOX(-) (n = 4) mice (left) and OXMC DOX(-) (n = 7) mice (right). \*p\<0.05, paired t-test.\
Figure 6---source data 1.Source data for [Figure 6A-D](#fig6){ref-type="fig"}.](elife-54275-fig6){#fig6}

###### Tactile stimulation during cataplexy in orexin- and MCH neuron-ablated mice.

###### Tactile stimulation during DT sleep in orexin- and MCH neuron-ablated mice.

To further characterize DT sleep, we analyzed the position of mice in the home cage when DT sleep was initiated. The cage was divided into 4 areas, with a nest located in one of them ([Figure 6B](#fig6){ref-type="fig"}). NREM and REM sleep occurred with higher probability when mice were in the nest area (NREM sleep: 76 ± 4.4%, REM sleep: 87 ± 7.0%, n = 6; [Figure 6B](#fig6){ref-type="fig"} bar graph). However, both DT sleep and cataplexy occurred in the nest area at almost a chance level (25%, [Figure 6B](#fig6){ref-type="fig"}). These results suggest that DT sleep occurs with a similar timing to cataplexy and, like cataplexy, may be a spontaneous, uncontrolled state.

We next categorized behaviors before cataplexy or DT sleep initiation by video analysis. The probability of running before cataplexy was significantly higher than running before DT sleep ([Figure 6C](#fig6){ref-type="fig"}). In comparison, the probability of grooming behavior before DT sleep was significantly higher than grooming before cataplexy ([Figure 6C](#fig6){ref-type="fig"}). Although the probabilities differed with some behaviors such as running and grooming, both DT sleep and cataplexy often occurred after running or digging. These results suggest that DT sleep can occur under situations similar to cataplexy.

Day- and night-time differences in cataplexy or DT sleep were also analyzed. As described previously ([@bib55]), orexin-ablated mice (OX DOX(-)) experienced more cataplexy during the dark phase than during the light phase ([Figure 6D](#fig6){ref-type="fig"}). In contrast, there was no substantial difference in cataplexy occurrence between the light and dark phases in OXMC DOX(-) mice, although DT sleep occurred more frequently in the dark phase compared to the light phase ([Figure 6D](#fig6){ref-type="fig"}). These results suggest that, even though MCH neuron ablation alone does not result in cataplexy, MCH neuron activity might be involved in the temporal regulation of cataplexy during both the light and dark phases.

Pharmacological assessments of DT sleep {#s2-5}
---------------------------------------

To further understand whether DT sleep is related to sleep or cataplexy, OXMC DOX(-) mice were exposed to chocolate to increase cataplexy, administered clomipramine to suppress cataplexy, or modafinil to promote wakefulness. After removing DOX chow for 4 weeks to generate dual orexin and MCH neuron ablation, DOX chow was replaced to stop further ablation and arrest further progress of sleep/wakefulness abnormalities ([@bib55]). The experimental protocols are illustrated in [Figures 7A](#fig7){ref-type="fig"}, [8A](#fig8){ref-type="fig"} and [9A](#fig9){ref-type="fig"}. Briefly, chocolate (1.7--1.9 g, milk chocolate, Meiji) was provided for 15 min just prior to dark onset (ZT12) for 3 days and sleep/wakefulness was analyzed on the third day. After a one-day interval, the vehicle, clomipramine or modafinil was administered followed by counterbalanced treatments on subsequent days. All administrations were performed just before dark onset.

![Effects of chocolate availability on DT sleep and cataplexy in OXMC mice.\
(**A**) Schematic showing the experimental protocol of chocolate availability in OXMC DOX(-) mice (n = 8). To avoid further neuron degeneration during the test, DOX chow was re-introduced after 4 weeks in the DOX(-) condition; light blue bar indicates this DOX(+) condition. Light-dark phases are indicated as white and black bars. Chocolate was made available for 15 min prior to light offset (19:45-20:00). (**B**) Hourly amounts of time, number of bouts and mean bout duration for each vigilance state during the first 6 hr of the dark phase after chocolate administration. Values are mean ± SEM. (**C**) Total time, number of bouts and mean bout duration for each vigilance state during the first 6 hr of the dark phase after chocolate administration. \*p\<0.05, vs control or vehicle. Values are mean ± SEM. Data were analyzed by paired t-test.\
Figure 7---source data 1.Source data for [Figure 7B and C](#fig7){ref-type="fig"}.](elife-54275-fig7){#fig7}

![Effects of clomipramine on DT sleep and cataplexy in OXMC DOX(-) mice.\
(**A**) Schematic showing the experimental protocol for clomipramine administration (15 mg/kg, i.p.) in OXMC DOX(-) mice (n = 8). To avoid further neuron degeneration during the test, DOX chow was re-introduced after 4 weeks in the DOX(-) condition; light blue bar indicates this DOX(+) condition. Light-dark phases are indicated as white and black bars. Clomipramine or vehicle was administered by i.p. injection prior to dark onset (19:45-20:00) as indicated by the arrows. (**B**) Hourly amounts of time, number of bouts and mean bout duration for each vigilance state during the first 6 hr of the dark phase after clomipramine administration. Values are mean ± SEM. (**C**) Total time, number of bouts and mean bout duration for each vigilance state during the first 2 hr of the dark phase after clomipramine administration. \*p\<0.05, vs control or vehicle. Values are mean ± SEM. Data were analyzed by paired t-test.\
Figure 8---source data 1.Source data for [Figure 8B and C](#fig8){ref-type="fig"}.](elife-54275-fig8){#fig8}

![Effects of modafinil on DT sleep and cataplexy in OXMC DOX(-) mice.\
(**A**) Schematic showing the experimental protocol for modafinil administration (100 mg/kg, i.p.) in OXMC DOX(-) mice (n = 8). To avoid further neuron degeneration during the test, DOX chow was re-introduced after 4 weeks in the DOX(-) condition; light blue bar indicates this DOX(+) condition. Light-dark phases are indicated as white and black bars. Modafinil or vehicle was administered by i.p. injection prior to dark onset (19:45-20:00) as indicated by the arrows. (**B**) Hourly amounts of time, number of bouts and mean bout duration for each vigilance state during the first 6 hr of the dark phase after modafinil administration. Values are mean ± SEM. (**C**) Total time, number of bouts and mean bout duration for each vigilance state during the first 3 hr of the dark phase after modafinil administration. \*p\<0.05, vs control or vehicle. Values are mean ± SEM. Data were analyzed by paired t-test.\
Figure 9---source data 1.Source data for [Figure 9B and C](#fig9){ref-type="fig"}.](elife-54275-fig9){#fig9}

Chocolate availability is known to increase the time in cataplexy and the number of cataplexy bouts in *Hcrt* knockout mice ([@bib10]; [@bib42]). Chocolate administration to OXMC DOX(-) mice significantly increased the total time in wakefulness and decreased REM and NREM sleep but did not affect total time or the number of bouts of DT sleep ([Figure 7B and C](#fig7){ref-type="fig"}). Clomipramine administration significantly decreased time in wakefulness and REM sleep and increased total time of NREM sleep. As expected, clomipramine also significantly inhibited cataplexy but did not affect DT sleep time, the number of bouts or their duration ([Figure 8B and C](#fig8){ref-type="fig"}). On the other hand, modafinil administration increased the total time of wakefulness, inhibited NREM and REM sleep and, as expected, did not affect cataplexy. Although the total time in DT sleep was not significantly affected by modafinil administration, the mean DT sleep bout duration was reduced ([Figure 9B and C](#fig9){ref-type="fig"}). These results suggest that the neural mechanisms underlying DT sleep might be distinct from those underlying cataplexy.

Relationship between DT sleep and the transition from NREM to REM sleep {#s2-6}
-----------------------------------------------------------------------

Since both δ and θ power in the EEG were high during DT sleep ([Figure 3D and E](#fig3){ref-type="fig"}), we evaluated the EEG during sleep/wake and wake/sleep transitions to compare EEG spectral characteristics. We found that the EEG spectrum in the transition from NREM to REM sleep was similar to DT sleep. We analyzed the last 3 epochs (12 s) in NREM sleep prior to transition to REM sleep in OXMC DOX(-) mice and compared them to the EEG power spectra in DT sleep ([Figure 10A](#fig10){ref-type="fig"}). The EEG spectra during the transition from NREM sleep to REM sleep was not altered by dual orexin and MCH neuron ablation ([Figure 10B](#fig10){ref-type="fig"}). Spectral power in the δ, θ, α and β bands of the EEG was indistinguishable between DT sleep and the NREM to REM sleep transition ([Figure 10C](#fig10){ref-type="fig"}). In addition, the 24 hr EMG integral did not differ between DT sleep and the NREM to REM transition ([Figure 10C](#fig10){ref-type="fig"}). These results indicated a similarity between DT sleep and the transition state from NREM to REM sleep.

![Comparison of EEG spectral power during DT sleep to the transition from NREM to REM sleep.\
(**A**) Typical traces of EEG and EMG during the transition from NREM to REM sleep (upper) and during DT sleep (lower). Three epochs during the transition from NREM sleep to REM sleep were analyzed. (**B**) Comparison of relative EEG power during the transition from NREM to REM sleep in OXMC DOX(-) mice during ablation (0, 3, and 4 weeks DOX(-)).The upper graph shows relative EEG power distribution. The lower bar graph shows the relative EEG power in each spectral band (δ, θ, α and β). Values are mean ± SEM. Data were analyzed by one-way ANOVA followed by the Bonferroni *post hoc* test. (**C**) Comparison of relative EEG power and EMG integral (inset) during DT sleep and the transition from NREM to REM sleep in OXMC DOX(-) mice. Upper graph shows relative EEG power distribution; lower bar graph shows relative EEG power in each band (δ, θ, α and β). Values are mean ± SEM. Paired t-test.\
Figure 10---source data 1.Source data for [Figure 10B and C](#fig10){ref-type="fig"}.](elife-54275-fig10){#fig10}

Discussion {#s3}
==========

To understand functional interactions between orexin and MCH neurons in the regulation of sleep and wakefulness, we generated dual orexin and MCH neuron-ablated mice and compared the resultant sleep abnormalities to those of orexin neuron-ablated mice. Double-ablated mice exhibited pronounced cataplexy and the total time in cataplexy and mean cataplexy bout duration were significantly increased, suggesting that MCH neurons normally have a suppressive role on cataplexy. Double-ablated mice also had exaggerated sleep abnormalities compared to singly-ablated or intact mice; specifically, increased time in wakefulness and decreased time in NREM and REM sleep. Double-ablated mice also exhibited a novel state that we called DT sleep, defined as an episode of sudden behavioral arrest of brief (\~15 s) duration preceded by at least 40 s of wake and characterized by high δ and θ power in the EEG. Behavioral, electrophysiological and pharmacological assessments discriminated DT sleep from NREM, REM and cataplexy.

Cataplexy is well-known to be triggered by strong positive emotions ([@bib38]). Previously we showed that cataplexy is prevented by orexin but not by other co-localized neurotransmitters in the orexin neurons, such as glutamate and dynorphin ([@bib13]). Orexin neuron activity is thought to prevent cataplexy through activation of OX2R when positive emotion occurs since *Hcrt* or *Hcrtr2* gene knockout or ablation of orexin neurons induces cataplexy. The amygdala is implicated in the emotional stimulation that facilitates cataplexy ([@bib10]; [@bib20]; [@bib21]; [@bib33]; [@bib54]). Neurons in the amygdala project to the brainstem, which is crucial for the regulation of muscle tone and REM sleep ([@bib63]). Serotonergic neurons in the raphe nucleus projecting to the amygdala are thought to be the neural pathway responsible for suppression of cataplexy by orexin neurons, since activation of serotonergic neurons or activation of serotonergic nerve terminals in the amygdala prevents cataplexy ([@bib20]; [@bib21]). Here, we show that MCH neurons decrease cataplexy duration but not cataplexy bout frequency. This difference might suggest that the mechanism of MCH neurons to prevent cataplexy is different from that of serotonergic neurons.

Our in situ hybridization results as well as previous reports ([@bib36]; [@bib37]) suggest that both orexin and MCH neurons are glutamatergic neurons. Among LH glutamatergic neurons, these two types of neurons are a relatively minor population (the proportion of MCH neurons and orexin neurons was 15% and 24%, respectively). These results suggest that ablation of a small number of additional LH glutamatergic neurons (10--15%) that co-express MCH exacerbates the narcolepsy phenotype in orexin neuron-ablated mice, underscoring the important role of MCH neurons to suppress cataplexy.

Neurons in the amygdala innervate and suppress the ventrolateral periaqueductal grey (vlPAG/LPT), DR, LC and tuberomammilary nucleus (TMN), areas that are known to be involved in the regulation of REM sleep or cataplexy ([@bib10]). It has been reported that MCH neurons also inhibit DR, LC, TMN and vlPAG neurons ([@bib57]; [@bib50]; [@bib16]; [@bib25]). These areas might be part of the neural circuit contributing to cataplexy prevention since MCH neurons may innervate different types of neurons in these areas. Alternatively, other downstream targets of MCH neurons such as the sublaterodorsal tegmental nucleus might be involved in the regulation of cataplexy and REM sleep ([@bib9]; [@bib39]). Recently, chemogenetic activation of MCH neurons in *Hcrt* knockout mice was shown to increase cataplexy bout duration without affecting the number of bouts ([@bib40]), a finding that is inconsistent with our results. However, the absence of orexin during development in constitutive *Hcrt* knockout mice might induce compensatory changes in neural circuitry, since *Hcrt* knockout mice have many fewer cataplexy bouts per night than DTA mice in which orexin neurons are ablated after maturation ([@bib55]). In addition, the chemogenetic activation paradigm used by Naganuma et al. could have induced strong activation of MCH cells above the physiological range. Recently, we reported that MCH neurons can be divided in three types by activation pattern: wake-active, REM-active and wake- and REM-active ([@bib24]). Activation of wake-active MCH neurons within the physiological range in orexin neuron-ablated mice would likely be valuable to further understand the role of MCH neurons in cataplexy.

Orexin- and MCH-neurons double-ablated mice frequently displayed brief (\~15 s) episodes of behavioral arrest during wakefulness that we called DT sleep, which was characterized by high power δ and θ waves in the EEG with low EMG amplitude. The first appearance of DT sleep was at 1 week DOX(-), which was sooner after DOX removal than the appearance of cataplexy at 2 weeks and suggests that DT sleep may be due to a smaller reduction in the number of orexin and MCH neurons. When initially observed, we assumed that DT sleep was cataplexy since both behaviors shared the characteristic of sudden behavioral arrest during wakefulness. However, the EEG spectrum was clearly distinct from cataplexy. Another critical difference between DT sleep and cataplexy was that mice responded to tactile stimulation by immediately returning to wakefulness from DT sleep but not from cataplexy. Furthermore, the behavioral arrest of DT sleep was observed without complete muscle atonia; thus, mice could maintain posture during DT sleep. This observation underscores the difference between DT sleep and cataplexy, since muscle atonia is an indispensable component of cataplexy.

Pharmacological assessments further confirmed differences between DT sleep and cataplexy. Chocolate is known to increase cataplexy by activating the prefrontal cortex and amygdala ([@bib10]). Chocolate increased cataplexy in double-ablated mice, but did not increase DT sleep. Clomipramine is a selective serotonin reuptake inhibitor that can inhibit REM sleep and cataplexy ([@bib65]). Clomipramine significantly decreased cataplexy in double-ablated mice, but did not affect the number of bouts or mean bout duration of DT sleep. Modafinil is known to be a dopamine reuptake inhibitor that can promote wakefulness ([@bib66]). Although modafinil significantly increased wakefulness, decreased NREM sleep and decreased the duration of DT sleep, the number of DT bouts was unaffected. Based on these results, DT sleep is classified as sleep but is distinct from NREM or REM sleep. Modafinil decreased the duration of DT sleep and DT sleep was often observed after grooming behavior, suggesting that dopaminergic neurons might be involved in the initiation of DT sleep since dopaminergic neurons are activated during grooming ([@bib18]; [@bib14]).

The transition from NREM to REM sleep is well known to be characterized by relatively high power in δ and θ waves ([@bib5]). Thus, we compared DT sleep to the transition from NREM to REM sleep. We found that δ, θ, α and β wave power were not significantly different between DT sleep and NREM to REM sleep transitions. The activity of orexin neurons is high in wakefulness and low in NREM and REM sleep ([@bib32]). In comparison, the activity of MCH neurons is high in REM sleep and low in NREM sleep and wakefulness ([@bib22]; [@bib7]; [@bib24]). Therefore, the minimum activity of these two types of neurons should occur just before initiation of REM sleep. It is possible that this transition might be manifest as DT sleep, since the brains of dual orexin- and MCH neuron-ablated mice are similar to conditions in which both orexin neurons and MCH neurons are inactive. Furthermore, NREM and REM sleep were attenuated in double-ablated mice, suggesting that DT sleep enables a compensatory role of both NREM and REM sleep. Whereas the loss of orexin neurons in narcolepsy has been proposed to disrupt a 'flip/flop switch' that facilitates the normal transition from wakefulness to sleep ([@bib49]), the dual loss of orexin and MCH neurons appears to prolong the normal transition from NREM to REM sleep through the DT sleep state.

To date, specific degeneration of MCH neurons has not been reported in humans. Ablation of MCH neurons in mice induces a relatively weaker effect on sleep and wakefulness compared with ablation of orexin neurons ([@bib55]; [@bib60]). MCH concentration in cerebrospinal fluid is not typically measured in sleep disorders patients. However, a patient with hypersomnia had low concentrations of both orexin (95 pg/ml) and MCH peptide (6 pg/ml) in the cerebrospinal fluid (Wada et al., Japan sleep annual meeting 2018, P-128). Detailed study of this and similar cases will help to understand the role of MCH neurons on sleep/wakefulness in humans.

Here, we revealed a new role of MCH neurons to prevent cataplexy and regulate sleep and wakefulness. Orexin neurons and MCH neurons interact in the hypothalamus and potentially in terminal projection sites to influence sleep/wake control. Since human studies have already suggested interaction between these two systems ([@bib8]), further investigations are warranted to reveal the regulatory mechanisms underlying the roles of these two systems in the control of sleep/wakefulness and cataplexy.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                      Designation                                        Source or\                                           Identifiers                                                                       Additional\
  (species) or\                                                                         reference                                                                                                                              information
  resource                                                                                                                                                                                                                     
  ---------------------------------- -------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------
  Genetic reagent (*Mus musculus*)   *Hcrt-tTA*                                         [@bib55]                                             RRID:[IMSR_APB:7778](https://scicrunch.org/resolver/IMSR_APB:7778)                

  Genetic reagent (*Mus musculus*)   *Pmch-tTA*                                         [@bib60]                                             RRID:[IMSR_RBRC05844](https://scicrunch.org/resolver/IMSR_RBRC05844)              

  Genetic reagent (*Mus musculus*)   *TetO DTA*                                         Jackson lab                                          RRID:[IMSR_JAX:008468](https://scicrunch.org/resolver/IMSR_JAX:008468)            

  Genetic reagent (*Mus musculus*)   *Hcrt-tTA;TetO DTA*                                [@bib55]                                             RRID:[MGI:5583048](https://scicrunch.org/resolver/MGI:5583048)                    

  Genetic reagent (*Mus musculus*)   *Hcrt-tTA; Pmch-tTA; TetO DTA*                     This paper                                                                                                                             Mating of the *Hcrt-tTA; TetO DTA* with the *Pmch-tTA* mice

  Antibody                           Rabbit anti-Pmch antibody                          Sigma-Aldrich                                        RRID:[AB_260690](https://scicrunch.org/resolver/AB_260690)                        (1:1000)

  Antibody                           Goat polyclonal anti-Hcrt                          Santa Cruz Biotechnology                             RRID:[AB_653610](https://scicrunch.org/resolver/AB_653610)                        (1:1000)

  Antibody                           Mouse anti-tryptophan hydroxylase antibody         Sigma-Aldrich                                        RRID:[AB_261587](https://scicrunch.org/resolver/AB_261587)                        (1:500)

  Antibody                           Rabbit anti-tyrosine hydroxylase antibody          Merck                                                RRID:[AB_390204](https://scicrunch.org/resolver/AB_390204)                        (1:1000)

  Antibody                           Biotinylated horse anti-goat IgG antibody          Vector Laboratories                                  RRID:[AB_2336123](https://scicrunch.org/resolver/AB_2336123)                      (1:1000)

  Antibody                           Biotinylated goat anti-rabbit/mouse IgG antibody   Vector Laboratories                                  RRID:[AB_2313606](https://scicrunch.org/resolver/AB_2313606)                      (1:1000)

  Sequence-based reagent             *Hcrt*                                             ACD Bio                                              Cat No. 490461-C2; RRID:[SCR_012481](https://scicrunch.org/resolver/SCR_012481)   (1:1500)

  Sequence-based reagent             *Pmch*                                             ACD Bio                                              Cat No. 478721-C1; RRID:[SCR_012481](https://scicrunch.org/resolver/SCR_012481)   (1:1500)

  Sequence-based reagent             *Slc32a1* (vGAT)                                   ACD Bio                                              Cat No. 319191-C4; RRID:[SCR_012481](https://scicrunch.org/resolver/SCR_012481)   (1:750)

  Sequence-based reagent             *Slc17a6* (vGlut2)                                 ACD Bio                                              Cat No. 319171-C3; RRID:[SCR_012481](https://scicrunch.org/resolver/SCR_012481)   (1:750)

  Chemical compound, drug            Opal520                                            PerkinElmer                                          RRID:[SCR_012163](https://scicrunch.org/resolver/SCR_012163)                      (1:1000)

  Chemical compound, drug            Opal620                                            PerkinElmer                                          RRID:[SCR_012163](https://scicrunch.org/resolver/SCR_012163)                      (1:1000)

  Chemical compound, drug            Chocolate                                          Meiji                                                Milk chocolate                                                                    (1.7--1.9 g/once)

  Chemical compound, drug            Clomipramine                                       Sigma-Aldrich                                        C7291-1G; RRID:[SCR_008988](https://scicrunch.org/resolver/SCR_008988)            (15 mg/kg)

  Chemical compound, drug            Modafinil                                          Cephalon Inc (Teva Pharmaceutical Industries Ltd.)                                                                                     (100 mg/kg)

  Software, algorithm                Origin 2017                                        Lightstone                                           RRID:[SCR_014212](https://scicrunch.org/resolver/SCR_014212); version 2017        

  Software, algorithm                SleepSign                                          Kissei Comtec                                                                                                                          

  Software, algorithm                ImageJ                                             <https://imagej.nih.gov/ij/>                         RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Experimental procedures {#s4-1}
-----------------------

### Animal usage {#s4-1-1}

All experimental procedures were performed in accordance with the guide of the Institutional Animal Care and Use Committes at the Research Institute of Environmental Medicine at Nagoya University and SRI International. All efforts were made to decrease animal suffering and to minimize the number of animals used.

### Animals {#s4-1-2}

All male mice had a C57BL/6J background and were housed on a 12 hr dark-light cycle (light on clock time: 8:00-20:00). The room temperature (RT) was kept at 25 ± 2°C, and humidity was maintained between 40% to 60%. The light intensity was 200 to 300 lux. Food and water were provided ad libitum. *Hcrt-tTA* mice express the mammalianized tetracycline-controlled transcriptional activator (tTA) in orexin neurons controlled by human *Hcrt* promoter ([@bib48]; [@bib55]). *Pmch-tTA* mice express tTA in MCH neurons controlled by *Pmch* promoter ([@bib60]). *TetO DTA* mice express diphtheria toxinA (DTA) that is under control of the Tet-off system (B6.Cg-Tg (*TetO DTA*) 1Gfi/j, The Jackson Laboratory, USA). The tTA protein binds to the tetracycline operator (TetO) and promotes expression of DTA. Doxycycline (DOX)-containing chow (DOX chow) was produced by mixing 10% DOX powder (Kyoritus Seiyaku, Japan) with normal chow (Labo MR Stock, Nosan, Japan) at the final concentration of 100 mg/kg. *Hcrt-tTA* (Tg/-); *TetO DTA* (Tg/-); *Pmch-tTA* (Tg/-) mice (OXMC) expressed tTA exclusively in both orexin and MCH neurons. Removing DOX-containing chow resulted in ablation of orexin and MCH neurons ([@bib55]; [@bib60]). Mating mice were fed with DOX chow for at least 1 week before the start of mating. During the prenatal and early postnatal periods, DOX was supplied via maternal circulation or lactation. After weaning, mice were fed with DOX chow until the day of the experiment. Genotypes of mice were determined by polymerase chain reaction (PCR) and electrophoresis. Three pairs of primers were used to check the genotypes: *Hcrt-tTA* (5'-AAGTCGACGGTGTCTGGCGCTCAGGGTG-3', 5'-GCAGCGGCCATTCCTTGG-3'), *Pmch-tTA (5'-CCAGGGTCTCGTACTGCTTC-3', 5'-AAGCATCAAACTAAGGCCAC-3'),* and *TetO DTA* (5'-GGCATTATCCACTTTTAGTGC-3', 5'-AGCAGAGCTCGTTTAGTGAACCGT-3').

### EEG and EMG surgical procedure {#s4-1-3}

Male mice were anesthetized with 2% isoflurane (095--06573, FUJIFILM Wako Pure Chemical Corporation, Japan) and implanted with three EEG electrodes (U-1430--01, Wilco, Japan) on the skull and two EMG electrodes (AS633, Cooner wire, Mexico) in the rhomboid muscle at 10 weeks of age as previously described [@bib55]; [Figure 1C](#fig1){ref-type="fig"}). Carprofen (Zoetis Inc, Japan), 20 mg/kg (subcutaneous injection), was administered the day of, and the day after, surgery for its anti-inflammatory and analgesic properties. After surgery, mice were housed separately for about 7 days for recovery. A cable with a slip ring (Kissei Comtec Co., Ltd, Japan) was connected to mice in the cage for 7 days before the initiation of EEG and EMG recordings.

### Sleep/wake recordings {#s4-1-4}

EEG and EMG signals were filtered at EEG 1.5--30 Hz and at EMG 15--300 Hz and amplified by an amplifier (AB-610J, Nihon Koden, Japan). The digital sampling rate was 128 Hz. Animal behavior was monitored through a Charged Coupled Device (CCD) video camera (SPK-E700CHP1, Keiyo Techno, Japan) and an infrared activity sensor (Kissei Comtec). All EEG and EMG data were recorded by VitalRecorder (Kissei Comtec) and analyzed by SleepSign software (Kissei Comtec).

### Vigilance state analysis {#s4-1-5}

EEG analysis was performed by Fast Fourier Transform (FFT). Power spectra profiles over a 0--10 Hz window with 1 Hz resolution for δ (1 ≤ δ \<6 Hz) and θ (6 ≤ θ \<11 Hz) bandwidths were calculated. EEG and EMG were automatically screened in 4 s epochs by SleepSign and classified as previously reported ([@bib59]; [@bib55]; [@bib60]). Wake was characterized by high EMG amplitude or locomotion score with low EEG amplitude, NREM sleep was characterized by low EMG amplitude and high EEG δ power, and REM sleep was characterized by low EMG and low EEG amplitude with over 50% of θ activity. Cataplexy was defined by muscle atonia lasting more than 10 s after more than 40 s of wakefulness, and low amplitude with over 50% of θ activity in the EEG ([@bib51]). DT sleep was defined by the following criteria: (1) a period of behavioral arrest, (2) that was preceded by at least 40 s of wakefulness, (3) characterized by high δ and θ power (at least 60--80% of the δ power found in NREM sleep) in the EEG, (4) low EMG activity, and (5) was terminated by a return to wakefulnes. Vigilance state classifications were automatically assigned by SleepSign software and then visually corrected. The transition from NREM to REM sleep was identified as the three epochs (12 s) before a REM sleep bout. EEG power spectral density were analyzed and viewed using the Signal Processing Toolbox of Matlab (Mathworks, USA).

### Behavioral assessment {#s4-1-6}

Behaviors were manually identified from video recordings. Behaviors occurring during the 4 s epoch immediately preceding DT sleep or cataplexy bouts were analyzed and calculated as percentages of the total recording time.

### Tactile stimulation {#s4-1-7}

Tactile stimulation was performed by applying a gentle touch around the face using a brush during the light phase (11:00-18:00) ([Videos 2](#video2){ref-type="video"} and [3](#video3){ref-type="video"}). Six OXMC DOX(-) mice (20--26 weeks old) were studied. Stimulations were conducted when immobility had lasted at least 10 s during NREM sleep, cataplexy or DT sleep. The interval between individual stimulations was at least 1 min. Vigilance states that occurred after stimulation were identified.

### Identification of the location of each sleep/wake stage within the home cage {#s4-1-8}

We divided each home cage into four quadrants, one of which contained a nest ([Figure 6B](#fig6){ref-type="fig"}). The home cage quadrant in which each mouse was located at the beginning of each vigilance state was identified by video recording.

### Pharmacological treatments and chocolate application {#s4-1-9}

All administrations were performed before light offset (19:45-20:00). Chocolate (1.7--1.9 g, milk chocolate, Meiji) was placed into the cage and mice could freely access chow and water at the same time. Clomipramine (15 mg/kg) and modafinil (100 mg/kg) were administered by intraperitoneal (i.p.) injection. Clomipramine hydrochloride (C7291-1G, MilliporeSigma, USA) was dissolved in saline (035--081517, Otsuka Pharmaceutical Co., Ltd, Japan). Modafinil (Cephalon Inc, USA) was dissolved in 5% dimethyl sulfoxide (07-4875-5, MilliporeSigma) and the mixed solution was diluted in saline.

### Immunohistochemistry {#s4-1-10}

Mice were deeply anesthetized with an i.p. injection of somnopentyl (6.48 mg/kg) (Kyoritsu Seiyaku Corporation, Tokyo, Japan) and 3% isoflurane, and then sequentially perfused with saline and 10% formalin (066--03847, FUJIFILM Wako). The brains were removed and immersed in 10% formalin overnight at 4°C and then immersed in a 30% sucrose solution in PBS for at least 2 d. The brains were frozen in embedding solution (4583, Sakura Finetek Japan, Japan) and stored in a −80°C freezer. Brains were subsequently sectioned at 40 µm thickness in a cryostat (CM3050-S, Leica Microsystems K.K., Japan).

Coronal sections of mouse brains were placed in phosphate buffer (PBS) with 0.3% H~2~O~2~ (H1009-500ML, MilliporeSigma) to inactivate endogenous peroxidase for 40--45 min at RT. After washing three times for 10 min in PBS containing 0.25% Triton X-100 (35501--15, Nacalai Tesque, Japan) and 1% bovine serum albumin (A7905-500G, MilliporeSigma) (PBS-BX), brain sections were incubated in PBS-BX with rabbit anti-MCH antibody (1:1000, M8440, MilliporeSigma), goat anti-orexin-A antibody (1:1000, sc-8070, Santa Cruz, Dallas, USA), mouse anti-tryptophan hydroxylase antibody (1:500, T0678-100UL, MilliporeSigma), or rabbit anti-tyrosine hydroxylase antibody (1:1000, AB152, Merck, Germany) overnight at 4°C. Sections were washed 3 times for 10 min in PBS-BX and incubated with biotinylated horse anti-goat IgG antibody (1:1000, BA-9500, Vector Laboratories, USA) or biotinylated goat anti-rabbit/mouse IgG antibody (1:1000, BA-1000, Vector Laboratories) in PBS-BX for 2 hr at RT. Sections were then washed in PBS-BX 3 times for 10 min and reacted with avidin-biotin peroxidase complex (PK-6100, Vectastain, USA) dissolved in PBS-BX at RT for 30 min. After washing 3 times for 10 min in PBS-BX, bound-peroxidase was visualized by DAB-buffer tablets (1.02924.0001, Merck) in distilled water with 0.0015% H~2~O~2~ resulting in a golden-brown reaction product. For two-color staining, the process described previously was performed twice. The 2^nd^ staining process used the DAB solution mixed with 2.5% ammonium nickel (II) (140--01015, FUJIFILM Wako), resulting in a black reaction product.

After staining, sections were mounted and dried at RT. Sections were sequentially rinsed in 70%, 90%, 100% (twice, 057--00451, FUJIFILM Wako) ethanol and xylene (twice, 244--00081, FUJIFILM Wako) for 30 s each. Brain sections were then mounted by Entellan (1.07961.0100, Merck) and dried at RT. Photomicrographs were obtained using a microscope (BZ-9000, Keyence, Japan). Every fourth section in the LH was used for cell counting (ImageJ).

### Statistical analyses {#s4-1-11}

Data were analyzed by paired or unpaired *t*-test using Excel (Microsoft, USA) or one-way Analysis of Variance (ANOVA) (with/without repeated measures) followed by Bonferroni's *post hoc* test using OriginPro 2017 software (ORIGIN 2017 Graphing and Analysis, OriginLab, USA).

### In situ RNA hybridization by RNAscope {#s4-1-12}

Mouse brains were isolated as described in the Immunohistochemistry section above. After freezing in embedding solution at −80°C, embedded brains were sectioned at 25 µm thickness and mounted on glass slides. The slides were then treated with RNAscope multiplex fluorescent v2 (\#323100, Advanced Cell Diagnostics, Hayward, CA) according to the RNAscope standard protocol. Briefly, slides were incubated with hydrogen peroxide at RT for 10 min, followed by boiling with target retrieval reagent at 98 \~ 102°C for 5 min, and protease digestion (Protease III) at 40°C in an HybEZ hybridization oven (Advanced Cell Diagnostics) for 30 min. Subsequently, slides were incubated at 40°C with target probes for 2 hr and slides were then washed in wash buffer (WB) twice (2 min each) at room temperature. Sections were then incubated in AMP1 buffer for 30 min, AMP2 buffer for 30 min, and AMP3 buffer for 15 min. After each hybridization step, slides were washed twice in WB. For fluorescent detection, the RNA probes were conjugated to Opal 520 or 620 with the TSA Plus Fluorescence system (Perkin Elmer, Waltham, MA). Slices were mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific, Waltham, MA). One fourth of brain slices were randomly chosen from 5 mice for four in situ hybridization combinations, as illustrated in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. A dotted circle (diameter: 1.2 mm) was located within the core LH region where orexin and MCH neurons are at a high density and the number of neurons were counted inside the circle as shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. The zona incerta, medial globus pallidus, and ventromedial hypothalamus were excluded from counting.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The mouse model with effective ablation of both orexin and MCH cells provide a powerful tool for studying the interaction between the two systems in sleep control. We found the behavioral characterization thorough and convincing. The study represents significant contribution to understanding normal and impaired sleep control.

**Decision letter after peer review:**

Thank you for submitting your article \"Dual Orexin and MCH neuron-ablated mice display severe sleep attacks and cataplexy\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Yang Dan as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Laura Colgin as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Shinjae Chung (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Previous studies showed that killing orexin neurons decreases wakefulness and causes narcolepsy, and killing MCH neurons increases wakefulness. But how these two closely located neuronal population interact was unclear. Hung et al., ablate MCH, Orexin/Hypocretin or both to understand how these neuropeptide systems contribute to sleep and wake regulation. They performed thorough analyses to examine their sleep/wake patterns, and found that the double-ablated mice show increased wakefulness and decreased REM and NREM sleep, but cataplexy bout duration and total time also increased compared to orexin neuron-ablation only, suggesting that MCH neurons also suppress cataplexy. These results reveal previously unknown interactions between orexin and MCH systems.

The mice they generated allow very effective ablation of both cell types, and they provide a powerful tool for studying the interaction between the two systems. The behavioral characterization is thorough, and the data are very convincing. The distinction between DT sleep, normal sleep and cataplexy is quite useful, and the nest analysis in Figure 6 is particularly informative.

Essential revisions:

\- Is there reason to believe that narcoleptics or any other sleep related neurological syndrome is linked to MCH cell loss? Why doesn\'t loss of MCH neurons alone cause cataplexy? The authors state: \"However, it is possible that both orexin and MCH neurons degenerate in some narcolepsy patients with severe cataplexy or hypersomnia.\" Anything \"is possible\" but they have no evidence for this. It seems that this analysis could easily be done on existing CSF samples available in both Japan and the US. Why not do this before publication? The authors should at least add more discussions on these points.

\- Number of mice used in Figure 7, Figure 8 and Figure 9 is not shown.

\- Figure 4. According to the figure legend, Figure 3A shows the \"Relative EEG power in three strains of mice in the DOX(+) condition during the dark phase.\" Similarly, the main text (subsection \'Dual ablated mice frequently displayed short behavioral arrests with high spectral power in the δ and θ bands of the EEG during wakefulness\') also mentions three groups tested \"in DOX(+) condition\". But the legend in the Figure 4A (on the upper right) shows OXMC mice DOX(-), OXMC mice DOX(+), OX mice DOX(-). I suspect that the figure legend is correct?

\- Figure 4D. For better comparison, could the authors include a comparison of the EMG amplitude during the different states?

\- Figure 10. For better comparison, could the authors also compare the EMG amplitudes during DT sleep and NREM to REM transitions?

\- The finding that MCH neurons also suppress cataplexy is interesting and surprising. One question is whether this is specific to MCH neurons or general to other GABAergic neurons in the same region. I am not sure if it\'s feasible to add a control experiment by ablating a similar number of neurons in the lateral hypothalamus that are not necessarily MCH neurons. If not, the authors can perhaps add a discussion of this point.

10.7554/eLife.54275.sa2

Author response

> Previous studies showed that killing orexin neurons decreases wakefulness and causes narcolepsy, and killing MCH neurons increases wakefulness. But how these two closely located neuronal population interact was unclear. Hung et al., ablate MCH, Orexin/Hypocretin or both to understand how these neuropeptide systems contribute to sleep and wake regulation. They performed thorough analyses to examine their sleep/wake patterns, and found that the double-ablated mice show increased wakefulness and decreased REM and NREM sleep, but cataplexy bout duration and total time also increased compared to orexin neuron-ablation only, suggesting that MCH neurons also suppress cataplexy. These results reveal previously unknown interactions between orexin and MCH systems.
>
> The mice they generated allow very effective ablation of both cell types, and they provide a powerful tool for studying the interaction between the two systems. The behavioral characterization is thorough, and the data are very convincing. The distinction between DT sleep, normal sleep and cataplexy is quite useful, and the nest analysis in Figure 6 is particularly informative.
>
> Essential revisions:
>
> \- Is there reason to believe that narcoleptics or any other sleep related neurological syndrome is linked to MCH cell loss? Why doesn\'t loss of MCH neurons alone cause cataplexy? The authors state: \"However, it is possible that both orexin and MCH neurons degenerate in some narcolepsy patients with severe cataplexy or hypersomnia.\" Anything \"is possible\" but they have no evidence for this. It seems that this analysis could easily be done on existing CSF samples available in both Japan and the US. Why not do this before publication? The authors should at least add more discussions on these points.

We have previously shown that ablation of MCH neurons alone does not induce cataplexy-like behavioral arrests but affects both sleep/wakefulness and memory in mice. Specifically, MCH neuron-ablated mice increased wakefulness and decreased NREM sleep without affecting REM sleep amount (Tabuchi et al., 2014) and also improved retention hippocampus-dependent memories (Izawa et al., 2019). These facts suggest that MCH neurons have multiple roles in the regulation of sleep/wakefulness and memory.

Regarding the possibility of humans with degeneration of both orexin and MCH neurons: this suggestion is based on a collaboration with clinical investigators that is beyond the scope of the present study. Although the results have not yet been published, a patient with hypersomnia that had low concentrations of both orexin (95 pg/ml) and MCH peptide (6 pg/ml) in the CSF was reported (Wada et al., 2018).

We modified the sentence in the Discussion as follows:

â€œHowever, a patient with hypersomnia had low concentrations of both orexin (95 pg/ml) and MCH peptide (6 pg/ml) in the cerebrospinal fluid (Wada et al., 2018). Studying this case in detail will help to understand the role of MCH neurons on sleep/wakefulness in humans.

> \- Number of mice used in Figure 7, Figure 8 and Figure 9 is not shown.

We added the number of mice used in the legend of Figure 7, Figure 8 and Figure 9.

Figure 7: n=8, Figure 8: n=8, Figure 9: n=8.

> \- Figure 4. According to the figure legend, Figure 3A shows the \"Relative EEG power in three strains of mice in the DOX(+) condition during the dark phase.\" Similarly, the main text (subsection \'Dual ablated mice frequently displayed short behavioral arrests with high spectral power in the δ and θ¸ bands of the EEG during wakefulness\') also mentions three groups tested \"in DOX(+) condition\". But the legend in the Figure 4A (on the upper right) shows OXMC mice DOX(-), OXMC mice DOX(+), OX mice DOX(-). I suspect that the figure legend is correct?

We are sorry for the confusion. Figure 3A indicates representative traces of EEG and EMG with power spectral analysis of 3 different groups (OXMC DOX(-), OXMC DOX(+) and OX DOX(-)) after 4 weeks DOX (-) or DOX (+). Figure 4A showed FFT spectral analysis of 3 different groups (OXMC DOX(-), OXMC DOX(+) and OX DOX(-)) before DOX removal (0w).

To clarify, we have added the following sentence in the Figure 4 legend. \"Relative EEG power in three strains of mice in the DOX(+) condition (before DOX removal) during the dark phase.\"

> \- Figure 4D. For better comparison, could the authors include a comparison of the EMG amplitude during the different states?

Thank you for your suggestion. We compared the EMG integral in each stage before and after DOX removal. The EMG integral did not significantly change after DOX removal. This data was added as Figure 4E. We added the following sentence in the Figure 4 legend. \"(E) EMG integral of OXMC mice after DOX (-) condition.\"

> \- Figure 10. For better comparison, could the authors also compare the EMG amplitudes during DT sleep and NREM to REM transitions?

Thank you for your advice. According to reviewer\'s suggestion, we analyzed the EMG integral during DT sleep and NREM to REM transitions in OXMC DOX(-) 4w mice. We added the average EMG integral for 24 hours as an inset of Figure 10C. The EMG integral was not significantly different between DT sleep and the NREM to REM transitions.

> \- The finding that MCH neurons also suppress cataplexy is interesting and surprising. One question is whether this is specific to MCH neurons or general to other GABAergic neurons in the same region. I am not sure if it\'s feasible to add a control experiment by ablating a similar number of neurons in the lateral hypothalamus that are not necessarily MCH neurons. If not, the authors can perhaps add a discussion of this point.

This is an interesting question. Based on Mickelsen et al., (Mickelsen et al., 2017; Mickelsen et al., 2019), MCH neurons express Glutamate decarboxylase 1 (Gad1) but not vesicular GABA transporter (vGAT). In addition, MCH neurons express vesicular glutamate transporter 2 (vGlut2). This means that, although MCH neurons are able to produce GABA, they do not release GABA; rather, they release glutamate. We confirmed this using RNAscope in situ hybridization to label MCH, orexin, vGAT and vGlut2. Figure 1---figure supplement 1 indicate that most MCH neurons and orexin neurons co-localize vGlut2 (MCH neurons: 96.3 ± 3.1%, n=4; orexin neurons: 99.6 ± 0.2%, n=5) but not vGAT (MCH neurons: 5.1 ± 0.9%, n=4; orexin neurons: 1.7 ± 0.9%, n=3), suggesting that most of MCH and orexin neurons are glutamatergic neurons rather than GABAergic neurons. In the center of lateral hypothalamic area (indicated by dashed circle in the pictures), MCH neurons and orexin neurons are a minor subset of the entire glutamatergic neuron population (MCH neurons: 14.6 ± 2.4% (n=4); orexin neurons: 23.6 ± 3.2% (n=5)). These results suggest that ablation of a small number (10-15%) of additional MCH/glutamatergic neurons in the lateral hypothalamic area exacerbated narcolepsy phenotypes in orexin neuron-ablated mice. Although it would be very difficult to ablate a similar number of glutamatergic non-MCH neurons in the lateral hypothalamus, we believe that these facts emphasize the important role of MCH neurons to suppress cataplexy.

We added the following sentences in the Results section and Discussion section.

Results section

\"In situ hybridization confirmed that MCH neurons and orexin neurons coexpressed vGlut2 mRNA but not vGAT mRNA. Figure 1---figure supplement 1 indicates that most MCH and orexin neurons are co-localized with vGlut2 (MCH neurons: 96.3 ± 3.1%, n=4; orexin neurons: 99.6 ± 0.2%, n=5) but not with vGAT (MCH neurons: 5.1 ± 0.9%, n=4; orexin neurons: 1.7 ± 0.9%, n=3), suggesting that most MCH and orexin neurons are glutamatergic rather than GABAergic neurons as also suggested by others (Mickelsen et al., 2017; Mickelsen et al., 2019). In the center of the LH (indicated by dotted circle), MCH neurons and orexin neurons were a relatively minor subset of the glutamatergic neuron population (MCH neurons: 14.6 ± 2.4% (n=4); orexin neurons: 23.6 ± 3.2% (n=5)).\"

Discussion section

\"Our in situ hybridization results as well as previous reports (Mickelsen et al., 2017; Mickelsen et al., 2019) suggest that both orexin and MCH neurons are glutamatergic neurons. Among LH glutamatergic neurons, these two types of neurons are a relatively minor population (the proportion of MCH neurons and orexin neurons was 15% and 24%, respectively). These results suggest that ablation of a small number of additional LH glutamatergic neurons (10-15%) that co-express MCH exacerbates the narcolepsy phenotype in orexin neuronablated mice, underscoring the important role of MCH neurons to suppress cataplexy.\"

[^1]: These authors contributed equally to this work.
